2 021 HHS National Blood Collection and Utilization Survey (NBCUS)
FACILITY NAME ___________________________ NBCUS ID ___________________________
Form Approved
OMB No. 0990-0313
Exp. Date:
xx/xx/xxxx
2021 National Blood
Collection and Utilization Survey
The Office of the
Assistant Secretary for Health and the Centers for Disease Control
and Prevention (CDC), Department of Health and Human Services (HHS),
are conducting the 2021 National Blood Collection and Utilization
Survey (NBCUS). The NBCUS is a biennial,
cross-sectional survey of all US blood collection centers and more
than 2,800 hospitals that transfuse blood and blood components. This
survey is used to characterize blood and blood component collection
and transfusion practices. The information is used to understand
blood demand and project future blood needs in the United
States.
The
2021 NBCUS covers the period of collection and utilization from
January 1, 2020 to December 31, 2021. Questions were added
specifically to gain information on the impact of COVID-19 on the
blood supply and utilization in 2020. Please assist us by completing
the online survey by June 11, 2022. The link to
complete the survey is included in an email sent to your facility and
is unique to your facility. Please do not share the link with
personnel outside your institution. Once you click the link (or copy
and paste into a browser window) you will be directed to the 2021
NBCUS Portal Page. On the Portal Page, you will find instructions for
completing the survey and a brief description of each section. If you
are not the appropriate person to complete any portion of the survey
or if you do not have all of the requested information, please
forward the link to the person in your institution who can best
provide the information.
Your
responses will remain anonymous in the final dataset. While results
of this survey will be released in aggregate form and data may be
made available in the form of a de-identified dataset, no specific
institutional identifiable information will be included.
According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0990-0313. The time required to complete this information collection is estimated to average 4 hours/ 0 minutes per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to U.S. Department of Health & Human Services, OS/OCIO/PRA, 200 Independence Ave., S.W., Suite 336-E, Washington D.C. 20201, Attention: PRA Reports Clearance Officer.
Please provide the contact information for the primary person
responsible for completing this section. Once you have submitted the
survey, a PDF including your responses will be sent to the email
address entered below. (*indicates a required field)
Prefix |
|
||
First Name1 |
|
||
Last Name1 |
|
||
Title/Position1* |
|
||
Work Phone number |
|
||
Work Email1* |
|
1Denotes fields that were pre-populated in the online survey based on previous correspondence.
Section B. Blood Collection, Processing, Testing, and Inventory Management
B1a. Does your institution collect blood from donors? (Even if you collect autologous units only, select “Yes.”)
Yes
No (if ‘No’, skip to section C)
B1b. If your facility is reporting data based on multiple facilities, please list the name of each facility below:
|
Facility Names |
B2a. During 2021, how many whole blood collection procedures were successfully completed by your institution in each of the following categories? Do not count low-volume or incomplete procedures. (*indicates a required field)
Allogeneic whole blood* |
|
||
Autologous whole blood* |
|
||
Directed whole blood* |
|
||
Total whole blood* |
|
B2b. During 2021, how many apheresis collections procedures1 (not components collected) were successfully completed by your institution in each of the following categories? Do not count low volume or incomplete procedures. (*indicates a required field)
Apheresis red blood cells only* |
|
||
Apheresis platelets only* |
|
||
Apheresis plasma only* |
|
||
Apheresis red blood cells AND platelets* |
|
||
Apheresis red blood cells AND plasma* |
|
||
Apheresis platelets AND plasma* |
|
||
Apheresis red blood cells AND platelets AND plasma* |
|
||
Total apheresis collection procedures (including all types of apheresis collections)* |
|
1For example, an apheresis collection that resulted in platelet and plasma units should be counted as a single platelet collection OR a single plasma collection, not counted under both.
B2c. During 2021, from the whole blood collection procedures recorded in B2a, how many units of whole blood for distribution as whole blood were prepared by your institution in each of the following categories?
Allogeneic whole blood |
|
||
Autologous whole blood |
|
||
Directed whole blood |
|
||
Total whole blood |
|
B2d. During 2021, from the whole blood collection procedures recorded in B2a, how many red blood cell units were prepared (i.e., separated from a unit of whole blood) by your institution in each of the following categories (* indicates a required field)?
Allogeneic whole blood-derived red blood cell units* |
|
||
Autologous whole blood-derived red blood cell units* |
|
||
Directed whole blood-derived red blood cell units* |
|
||
Total whole blood-derived red blood cell units* |
|
B2e. During 2021, from the apheresis collection procedures recorded in B2b, how many red blood cell units were collected by your institution in each of the following categories? (*indicates a required field)
Allogeneic apheresis red blood cell units* |
|
||
Autologous apheresis red blood cell units* |
|
||
Directed apheresis red blood cell units* |
|
||
Total apheresis red blood cell units* |
|
B2f. During 2021, from the whole blood collection procedures recorded in B2a, how many individual platelet units were prepared (i.e., separated from a unit of whole blood) by your institution?
1For example, if your institution pooled 5 individual platelet units per pool and manufactured 1000 pools of platelets, 5000 individual whole blood-derived platelet units should be recorded.
B2g. During 2021, from the apheresis collection procedures recorded in B2b, how many platelet units were collected by your institution in each of the following categories? (* indicates a required field)?
Allogeneic apheresis platelet units |
|
||
Single |
|
||
Double1 |
|
||
Triple1 |
|
||
Directed apheresis platelet units |
|
||
Total apheresis platelet units* |
|
1Count double collections as two units and triple collections as three units.
B2h. During 2021, what was the average number of individual platelet units included per pre-storage pool of whole blood-derived platelets?
|
Free text, numeric values only |
B2i. During 2021, from the apheresis collection procedures recorded in B2b, how many plasma units were collected by your institution?
Total apheresis plasma units |
|
B2j. During 2021, from the whole blood collection procedures recorded in B2a, how many plasma units were successfully prepared (i.e., separated from a unit of whole blood) by your institution?
Total whole blood-derived plasma units |
|
B2k. During 2021, how many units of group AB plasma were collected by your institution? (Count apheresis plus whole blood-derived units)
Group AB plasma |
|
B2l. During 2021, how many units of COVID-19 convalescent plasma were collected by your institution? (Count apheresis plus whole blood-derived units)
COVID-19 convalescent plasma1 |
|
1 Convalescent plasma collected from individuals who have recovered from COVID-19.
B2m. During 2021, from the whole blood collection procedures recorded in B2a, how many individual cryoprecipitated AHF units1 were successfully prepared by your institution? (* indicates a required field)
Individual cryoprecipitated AHF units* |
|
1For example, if your institution pooled 5 individual cryoprecipitated AHF units per pool and collected 1000 units, 5000 individual cryoprecipitated AHF units should be recorded. If your institution pooled 10 individual cryoprecipitated AHF units per pool and collected 1000 pools, 10,000 individual cryoprecipitated AHF units should be recorded.
B2n. During 2021, what was the average number of cryoprecipitated AHF units per whole blood-derived cryoprecipitated AHF pool?
|
Free text, numeric values only |
B2o. During 2021, how many granulocytes were collected by your institution?
Granulocyte units |
|
B3. During 2021, for each product, what was the total number of allogeneic units (non-directed and directed combined) discarded for: (*indicates a required field)
Reactive infectious disease testing results
Whole blood donation1* |
|
||
Apheresis red blood cells* |
|
||
Apheresis plasma* |
|
||
Apheresis platelets* |
|
All other reasons (e.g., low volume, broken bag, etc.) not including outdated components
Whole blood donation1* |
|
||
Apheresis red blood cells* |
|
||
Apheresis plasma* |
|
||
Apheresis platelets* |
|
1If any or all components of a whole blood-derived collection are discarded, please record it as one unit. For example, if either an entire whole blood collection or both the plasma and the red blood cells prepared from a single whole blood collection are discarded, it is counted as one unit discarded. If the plasma from a whole blood donation was discarded (i.e., the red blood cells from same donation is successfully distributed), it is also counted as one unit discarded.
B4a. During 2021, how many people presented to donate including successful and unsuccessful donations, and those who deferred (* indicates required field)?
Male |
|
||
Female |
|
||
Prefer other self-description1 |
|
||
Total* |
|
1“Prefer other self-description” includes anyone who does not identify as male or female and should be included as part of the total donors presenting to donate.
B4b. Please list categories which may be classified under “prefer other self-description”:
|
Sex or Gender Identities |
B5. During 2021, how many donors were deferred for the following reasons1:
Low hemoglobin or low hematocrit
Male |
|
||
Female |
|
||
Prefer other self-description2 |
|
||
Total |
|
Medication use
Total |
|
Pulse
Total |
|
Blood pressure
Total |
|
High-risk behavior (restricted to MSM)
Total |
|
High-risk behaviors (all other behaviors)
Total |
|
Travel and/or residence
Total |
|
Tattoo/piercing/scarring
Total |
|
Other non-medical reasons
Total |
|
Total presenting donors deferred for any reason
Male |
|
||
Female |
|
||
Prefer other self-description2 |
|
Total |
|
1If donor was deferred for multiple reasons, count all.
2“Prefer other self-description” includes anyone who does not identify as male or female and should be included as part of the total donors presenting to donate.
B6. During 2021, how many of the following types of donors did your institution successfully collect blood products from and how many donations did they make?
First-time allogeneic donors |
|
||
Donations from first time allogeneic donors |
|
||
Repeat allogeneic donors (count a single repeat donor only once) |
|
||
Donations from repeat allogeneic donors |
|
||
Directed donors |
|
||
Autologous donors |
|
B7. During 2021, how many allogeneic whole blood and apheresis red blood cell donations combined were successfully collected from the following donor age groups?1
Donors aged 15 years |
|
||
Donors aged 16 years |
|
||
Donors aged 17 years |
|
||
Donors aged 18 years |
|
||
Donors aged 19-24 years |
|
||
Donors aged 25-44 years |
|
||
Donors aged 45-64 years |
|
||
Donors aged 65-74 years |
|
||
Donors aged ≥75 years |
|
||
|
|
1Combine whole blood donations and apheresis red blood cell donations.
B8. During 2021, how many donations of allogeneic whole blood and red blood cell units were successfully collected from donors who identify as1:
Hispanic or Latino |
|
||
Black or African American |
|
||
Asian |
|
||
Native Hawaiian or Pacific Islander |
|
||
American Indian or Alaska Native |
|
1 More than one category can be selected for a single donor.
B9. How many severe donor-related adverse events1 were experienced by donors during 2021?
Whole blood collections
All donors |
|
||
Aged ≤18 years |
|
||
Aged ≥19 years old |
|
Apheresis collections
All donors |
|
||
Aged ≤18 years |
|
||
Aged ≥19 years |
|
1 AABB Donor Hemovigilance Working Group grade 2 or higher (e.g., adverse event with duration > 2 weeks; resulted in limitation in activities of daily living; or required transport to emergency department, sutures, or antibiotics). See https://www.aabb.org/docs/default-source/default-document-library/resources/severity-grading-tool-for-donor-adverse-events.pdf?sfvrsn=ff563263_4.
B10a. During 2021, how many units of whole blood intended for transfusion as whole blood were imported, distributed, and outdated by your institution? (*indicates required fields)
Imported whole blood intended for transfusion as whole blood
Allogeneic |
|
||
Autologous |
|
||
Directed |
|
||
Total* |
|
Distributed whole blood intended for transfusion as whole blood1 (collected and imported)
Allogeneic |
|
||
Autologous |
|
||
Directed |
|
||
Total* |
|
Outdated whole blood intended for transfusion as whole blood (collected and imported)
Allogeneic |
|
||
Autologous |
|
||
Directed |
|
||
Total* |
|
1Units distributed more than once (e.g., because they have been returned) should be counted only once.
B10b. During 2021, how many units of whole blood-derived red blood cells were imported, distributed, and outdated by your institution? (*indicates a required field)
Imported whole blood-derived red blood cells
Allogeneic |
|
||
Allogeneic group O+ |
|
||
Allogeneic group O- |
|
||
Autologous |
|
||
Directed |
|
||
Total* |
|
Distributed whole blood-derived red blood cells1 (collected and imported)
Allogeneic |
|
||
Allogeneic group O+ |
|
||
Allogeneic group O- |
|
||
Autologous |
|
||
Directed |
|
||
Total* |
|
Outdated whole blood-derived red blood cells (collected and imported)
Allogeneic |
|
||
Allogeneic group O+ |
|
||
Allogeneic group O- |
|
||
Autologous |
|
||
Directed |
|
||
Total* |
|
1Units distributed more than once (e.g., because they have been returned) should be counted only once.
B10c. During 2021, how many units of apheresis red blood cells were imported, distributed, and outdated by your institution? (* indicates required fields)
Imported apheresis red blood cells
Allogeneic |
|
||
Allogeneic group O+ |
|
||
Allogeneic group O- |
|
||
Autologous |
|
||
Directed |
|
||
Total* |
|
Distributed apheresis red blood cells1 (collected and imported)
Allogeneic |
|
||
Allogeneic group O+ |
|
||
Allogeneic group O- |
|
||
Autologous |
|
||
Directed |
|
||
Total* |
|
Outdated apheresis red blood cells (collected and imported)
Allogeneic |
|
||
Allogeneic group O+ |
|
||
Allogeneic group O- |
|
||
Autologous |
|
||
Directed |
|
||
Total* |
|
1Units distributed more than once (e.g., because they have been returned) should be counted only once.
B10d. During 2021, how many units of apheresis platelets were imported, distributed, and outdated by your institution? (*indicates a required field)
Imported apheresis platelets
Allogeneic |
|
||
Directed |
|
||
Total* |
|
Distributed apheresis platelets (including imported units)1 (collected and imported)
Allogeneic |
|
||
Single collection |
|
||
Double collection 1 |
|
||
Triple collection 1 |
|
||
Directed |
|
||
Total* |
|
Outdated apheresis platelets (collected and imported)
Allogeneic |
|
||
Directed |
|
||
Total* |
|
1Units distributed more than once (e.g., because they have been returned) should be counted only once.
B10e. During 2021, how many units of whole blood-derived platelets were imported, distributed, and outdated by your institution? (*indicates a required field)
Imported whole blood-derived platelets
Individual* |
|
||
Platelet pools1 |
|
Distributed whole blood-derived platelets2 (collected and imported)
Individual* |
|
||
Platelet pools1 |
|
Outdated whole blood-derived platelets (collected and imported)
Individual* |
|
||
Platelet pools1 |
|
1Number of platelet pools prepared from whole blood collections. Do not include the same platelet units in both the individual unit and platelet pool counts. For this question, individual units of whole blood-derived platelets and platelet pools are mutually exclusive.
2Units distributed more than once (e.g., because they have been returned) should be counted only once.
B10f. During 2021, how many units of apheresis plasma were imported, distributed, and outdated by your institution? (*indicates a required field)
Imported apheresis plasma
Total* |
|
Distributed apheresis plasma1 (collected and imported)
FFP2 |
|
||||
PF243 |
|
||||
PF24RT244 |
|
||||
Liquid |
|
||||
Jumbo FFP (>400 mL)5 |
|
||||
COVID-19 convalescent plasma6
Total* |
|
Outdated apheresis plasma (collected and imported)
Total* |
|
1Units distributed more than once (e.g., because they have been returned) should be counted only once.
2Fresh frozen plasma (FFP): plasma frozen at -18C or colder within 8 hours of collection.
3Plasma frozen within 24 hours of phlebotomy (PF24): plasma separated from the blood of an individual donor and placed at -18C or colder within 24 hours of collection from the donor.
4Plasma frozen within 24 hours of phlebotomy and held at room temperature up to 24 hours after phlebotomy (PF24RT24): plasma held at room temperature for up to 24 hours after collection and then frozen at -18C or colder.
5Plasma, Jumbo: FFP having a volume greater than 400 mL.
6Convalescent plasma collected from individuals who have recovered from COVID-19, including units collected under the EUA, units collected and distributed for clinical trials and units disseminated under emergency Investigational New Drug (eIND) application.
B10g. During 2021, how many units of whole blood-derived plasma were imported, distributed, and outdated by your institution? (*indicates a required field)
Imported whole blood-derived plasma
Total* |
|
Distributed whole blood-derived plasma1 (collected and imported)
Outdated whole blood-derived plasma (collected and imported)
1Units distributed more than once (e.g., because they have been returned) should be counted only once.
2Fresh frozen plasma (FFP): plasma frozen at -18C or colder within 8 hours of collection.
3Plasma frozen within 24 hours of phlebotomy (PF24): plasma separated from the blood of an individual donor and placed at -18C or colder within 24 hours of collection from the donor.
B10h. During 2021, how many units of group AB plasma were distributed and outdated by your institution? (collected and imported)
Units distributed1 |
|
||
Units outdated |
|
1Units distributed more than once (e.g., because they have been returned) should be counted only once.
B10i. During 2021, how many units of cryoprecipitated AHF were imported, distributed, and outdated by your institution? (*indicates a required field)
Imported cryoprecipitated AHF1
Individual units* |
|
||
Cryoprecipitated AHF pools1 |
|
Distributed cryoprecipitated AHF 2 (collected and imported)
Individual units* |
|
||
Cryoprecipitated AHF pools1 |
|
Outdated cryoprecipitated AHF (collected and imported)
Individual units* |
|
||
Cryoprecipitated AHF pools1 |
|
1Number of cryoprecipitated AHF pools prepared from whole blood collections. Do not include the same cryoprecipitated AHF units in both the individual unit and cryoprecipitated AHF pool counts. For this question, individual units of cryoprecipitated AHF and cryoprecipitated AHF pools are mutually exclusive.
2 Units distributed more than once (e.g., because they have been returned) should be counted only once.
B10j. During 2021, how many units of granulocytes were imported, distributed, and outdated by your institution? (*indicates a required field)
Imported granulocyte units* |
|
||
Distributed granulocyte units1* (collected and imported) |
|
||
Outdated granulocyte units* (collected and imported) |
|
1 Units distributed more than once (e.g., because they have been returned) should be counted only once.
B11a. During 2021, did your institution prepare apheresis platelets using platelet additive solution?
Yes
No (if ‘No’, skip to B12)
B11b. During 2021, how many apheresis platelet units were prepared using platelet additive solution?
|
Free text, numeric values only |
B12. During 2021, for each of the following categories, how many units did your institution collect, prepare, or modify to achieve pre-storage leukoreduction?
Whole blood units |
|
||
Whole blood-derived RBC units |
|
||
Apheresis RBC units |
|
||
Whole blood-derived platelet units |
|
B13. Does your facility use hematopoietic growth factor mobilization for granulocyte collections?
Yes
No
Not applicable because granulocytes are not collected
B14a. Does your institution type red blood cell antigens using a molecular assay (e.g., genotyping)?
Yes
No (if No, skip to B15)
B14b. How many red blood cell donors were typed using a molecular assay (e.g., genotyping)?
|
Number of donors |
B15a. During 2021, which of the following bacterial risk control strategies for platelets did your institution use? (select all that apply; if none are selected, skip to B16)
Primary culture performed no sooner than 24 hours
Large volume, delayed sampling no sooner than 36 hours
Large volume, delayed sampling no sooner than 48 hours
Pathogen reduction technology
B15b. During 2021, how many apheresis platelet units were distributed that were subjected to the following bacterial risk control strategies for platelets?
Primary culture performed no sooner than 24 hours
|
|
||
Large volume, delayed sampling no sooner than 36 hours |
|
||
Large volume, delayed sampling no sooner than 48 hours |
|
||
Pathogen reduction technology |
|
B16. During 2021, how many blood drives were cancelled?
|
Number of blood drives |
B17. During 2021, did your facility experience a shortage of any blood products?
Yes
No
Note: The following questions were added specifically to gain information on the impact of COVID-19 on the blood supply in 2020.
Supplemental Section B: Impact of COVID-19 Pandemic on Blood Collection and Distribution in 2020
SB1. During each month in 2020, how many whole blood collection procedures were successfully completed by your institution? Do not count low-volume or incomplete procedures.
January |
|
||
February |
|
||
March |
|
||
April |
|
||
May |
|
||
June |
|
||
July |
|
||
August |
|
||
September |
|
||
October |
|
||
November |
|
||
December |
|
SB2. During each month in 2020, how many units of apheresis platelets were distributed by your institution?
January |
|
||
February |
|
||
March |
|
||
April |
|
||
May |
|
||
June |
|
||
July |
|
||
August |
|
||
September |
|
||
October |
|
||
November |
|
||
December |
|
SB3. During 2020, did your institution collect convalescent plasma from donors?
Yes
No (if ‘No’, end of section supplemental section B)
SB4. During all months of 2020, how many COVID-19 convalescent plasma collection units were collected by your institution? Do not count low-volume or incomplete procedures. (*indicates a required field)
COVID-19 convalescent plasma1 |
|
1 Convalescent plasma collected from individuals who have recovered from COVID-19
Section C. Blood Transfusion
Please provide
the contact information for the primary person responsible for
completing this section.
Prefix |
|
||
First Name |
|
||
Last Name |
|
||
Title/Position |
|
||
Work Phone number |
|
||
Work Email |
|
C1. Is your institution directly involved in the transfusion of blood to patients? (NOTE: If your institution is a centralized transfusion service, your participating facilities may have been sent a link to complete the survey. If so, please answer “No” to this question and contact CDC at [email protected].)
Yes
No
(if ‘No’, end of section)
C2a. During 2021, did your facility transfuse whole blood? (i.e., whole blood that has not been separated into red blood cells, plasma, and/or platelets)?* (indicates a required question)
Yes
No (if ‘No’, skip to C3a)
C2b. During 2021, for allogeneic whole blood (i.e. that has not been separated into red blood cell, plasma, and/or platelets), how many units did your institution transfuse, how many recipients were transfused, and how many units were outdated? (* indicates required fields)
Allogeneic whole blood
Total units transfused* |
|
||
Total number of recipients |
|
||
Total outdated units* |
|
C3a. During 2021, for allogeneic red blood cells, how many units did your institution transfuse, how many recipients were transfused, and how many units were outdated? (* indicates required fields)
Allogeneic red blood cells (include all blood groups)
Total units transfused* |
|
||
Total number of recipients |
|
||
Total outdated units* |
|
C3b. During 2021, for group O+ and O- allogenic red blood cells, how many units did your institution transfuse and how many units were outdated?
Allogeneic Group O+ red blood cells
Total units transfused |
|
||
Total outdated units |
|
Allogeneic Group O- red blood cells
Total units transfused |
|
||
Total outdated units |
|
C4. During 2021, for directed and autologous allogenic whole blood and red blood cells, how many units did your institution transfuse, how many recipients were transfused, and how many units were outdated? (* indicates a required field)
Directed whole blood units1
Number of units transfused to intended recipient* |
|
||
Number of recipients |
|
||
Outdated units* |
|
Directed red blood cell units1
Number of units transfused to intended recipient* |
|
||
Number of recipients |
|
||
Outdated units* |
|
Autologous whole blood units
Number of units transfused to intended recipient* |
|
||
Number of recipients |
|
||
Outdated units* |
|
Autologous red blood cell units
Number of units transfused to intended recipient* |
|
||
Number of recipients |
|
||
Outdated units* |
|
1Directed units are those which have been donated by a family member or friend of the patient as a result of a patient request to be transfused with blood from a specific donor.
C5a. During 2021, how many units of each of the following components did your institution transfuse and how many units were outdated while on your shelf including units transfused to pediatric patients? (* indicates required fields)
Transfusions
Whole blood-derived platelets (pre-storage pooled and individual platelet concentrates expressed as pooled equivalents)1*
|
|
||
Apheresis platelet units 2* |
|
||
Directed platelets to intended recipients3 |
|
Outdates
Whole blood-derived platelets (pre-storage pooled and individual platelet concentrates expressed as pooled equivalents)4*
|
|
||
Apheresis platelet units (full unit)5* |
|
||
Directed platelets to intended recipients3 |
|
1Number of whole blood-derived platelet pools transfused. If any individual units of whole blood-derived platelets were transfused, convert these to a pooled equivalent. For example, if 200 platelet pools and 100 individual whole blood-derived platelet units were transfused and 5 individual platelet units are included per pool, then 220 units (200 + [100/5]) should be recorded.
2The number of apheresis platelet units transfused. In contrast to units of whole blood-derived platelets, no conversion calculation is needed.
3Directed units are those which have been donated by a family member or friend of the patient as a result of a patient request to be transfused with blood from a specific donor.
4Number of whole blood-derived platelet pools outdated. If any individual units of whole blood-derived platelets were outdated, convert these to a pooled equivalent. For example, if 200 platelet pools and 100 individual whole blood-derived platelet units were outdated and 5 individual platelet units are included per pool, then 220 units (200 + [100/5]) should be recorded. 5The number of apheresis platelet units outdated. In contrast to units of whole blood-derived platelets, no conversion calculation is needed.
C5b. During 2021, how many units of plasma did your institution transfuse and how many units were outdated while on your shelf including units transfused to pediatric patients? (* indicates required fields)
Transfusions
Total Plasma* |
|
Outdates
Total Plasma* |
|
C5c. Among plasma units included in the response to question C5b, during 2021, how many units of each of the following components did your institution transfuse and how many units were outdated while on your shelf including units transfused to pediatric patients?
Transfusions
Thawed plasma1 (i.e., used within 1-5 days of thaw) |
|
||
Liquid plasma (i.e., never frozen) |
|
||
Group AB plasma |
|
||
COVID-19 convalescent plasma |
|
Outdates
Thawed plasma1 (i.e., used within 1-5 days of thaw) |
|
||
Liquid plasma (i.e., never frozen) |
|
||
Group AB plasma |
|
||
COVID-19 convalescent plasma |
|
1 Thawed plasma: FFP, PF24, or PF24RT24 that has been thawed and held at 1 to 6 C for 1 to up to 5 days after thawing.
C5d. During 2021, how many units of each of the following components did your institution transfuse and how many units were outdated while on your shelf including units transfused to pediatric patients? (* indicates required fields)
Transfusions
Cryoprecipitated AHF individual units transfused*1 |
|
||
Cryoprecipitated AHF transfused pool size* |
|
||
Granulocytes units transfused* |
|
Outdates
Cryoprecipitated AHF individual units outdated*1 |
|
||
Granulocytes units outdated* |
|
1Number of individual cryoprecipitated AHF units transfused. Please convert pools of cryoprecipitated AHF to individual units. For example, if 200 pools of cryoprecipitated AHF were transfused and 5 individual units were included per pool, please record 1000 units (200 pools * 5 units/pool).
C6a. During 2021, did your facility transfuse blood to pediatric or neonatal patients? (Select all that apply)
Yes, pediatric (>4 months old)
Yes, neonatal (<=4 months old)
No (skip to C9a)
C6b. Indicate the total number of units transfused to pediatric and neonatal patients during 2021.
Number of units in whole or in part transfused for pediatric (>4 months old) patients1
Whole blood |
|
||
Red blood cells |
|
||
Plasma |
|
||
Apheresis platelets |
|
||
Whole blood-derived platelets |
|
||
Cryoprecipitated AHF |
|
Total number of pediatric (>4 months old) recipients that received the following blood components
Whole blood |
|
||
Red blood cells |
|
||
Plasma |
|
||
Apheresis platelets |
|
||
Whole blood-derived platelets |
|
||
Cryoprecipitated AHF |
|
Neonatal Transfusions
Number of units in whole or in part transfused for neonatal (≤4months old) patients1
Whole blood |
|
||
Red blood cells |
|
||
Plasma |
|
||
Apheresis platelets |
|
||
Whole blood-derived platelets |
|
||
Cryoprecipitated AHF |
|
Total number of neonatal (≤4months old) recipients that received the following blood components
Whole blood |
|
||
Red blood cells |
|
||
Plasma |
|
||
Apheresis platelets |
|
||
Whole blood-derived platelets |
|
||
Cryoprecipitated AHF |
|
1This should be a subset of data reported in the previous two questions. Pediatric aliquots should be recorded in standard unit equivalents. For example, if the standard red blood cell unit volume is 500mL and the volume of pediatric aliquots are 50mL (10 pediatric aliquots per standard unit), then record 150 pediatric aliquot transfusions as 15 units.
C6c. For neonatal patients, which of the following do you use for aliquots? (check all that apply)
Aliquots using syringes from full-size unit
Pedipacks
C6d. For neonatal patients, does your facility attempt to use aliquots from the same full-size unit for every transfusion?
Yes
No
C7a. Which of the following methods does your facility use to irradiate components? (check all that apply)
Cesium
X-Ray
Unknown, irradiation performed by another facility
C7b. Indicate how many irradiated (by any method) units for each of the following components your institution transfused in 2021. For pediatrics, use the number of adult equivalent units used in whole or part.1 For components that are irradiated and leukoreduced, include these in the count for both entries.
Whole blood units |
|
||
Red blood cell units |
|
||
Apheresis platelet units |
|
||
Whole blood-derived platelet units |
|
||
|
|
1Pediatric aliquots should be recorded in standard unit equivalents. For example, if the standard red blood cell unit volume is 500mL and the volume of pediatric aliquots are 50mL (10 pediatric aliquots per standard unit), then record 150 pediatric aliquot transfusions as 15 units. If only part of a standard unit is used and the rest is discarded, please record it as 1 standard unit.
C7c. Indicate how many leukoreduced units for each of the following components your institution transfused during 2021. For pediatrics, use the number of adult equivalent units used in whole or part.1 For components that are irradiated and leukoreduced, include these in the count for both entries.
Before Storage
Whole blood units |
|
||
Red blood cell units |
|
||
Whole blood-derived platelet units |
|
After Storage (including at the bedside)
Whole blood units |
|
||
Red blood cell units |
|
||
Whole blood-derived platelet units |
|
1Pediatric aliquots should be recorded in standard unit equivalents. For example, if the standard red blood cell unit volume is 500mL and the volume of pediatric aliquots are 50mL (10 pediatric aliquots per standard unit), then record 150 pediatric aliquot transfusions as 15 units. If only part of a standard unit is used and the rest is discarded, please record it as 1 standard unit.
C8a. During 2021, among transfused red blood cells, how many units were…
1-35 day(s) old |
|
||
36-42 days old |
|
C8b. During 2021, among transfused whole blood-derived platelets, how many units were…
1-3 day(s) old |
|
||
4-5 days old |
|
C8c. During 2021, among transfused apheresis platelets, how many units were…
1-3 day(s) old |
|
||
4-5 days old |
|
||
6-7 days old |
|
C9. If your facility pools whole blood-derived platelets, during 2021 at your institution, on average, how many individual platelet units were included in a post-storage pooled whole blood-derived platelet dose?
|
Number of individual units in a pool |
○
Not applicable
C10a. Indicate the number of red blood cell units that were transfused in the following inpatient and outpatient settings during 2021. (This can be determined by location or by physician use.)
All surgery (including transplant) |
|
||
Inpatient medicine (including hematology/oncology) |
|
||
Emergency Department |
|
||
Obstetrics/Gynecology |
|
||
Pediatrics, including critical care |
|
||
Neonates, including critical care |
|
||
Adult critical care |
|
||
Outpatient and non-acute inpatient settings1 |
|
1E.g., outpatient dialysis, rehabilitation, hospice, long term care, etc.
C10b. Indicate the number of platelet units that were transfused in the following inpatient and outpatient settings during 2021. (This can be determined by location or by physician use.) If whole blood-derived platelets were transfused, please convert them to pooled equivalent units.1
All surgery (including transplant) |
|
||
Inpatient medicine (including hematology/oncology) |
|
||
Emergency Department |
|
||
Obstetrics/Gynecology |
|
||
Pediatrics, including critical care |
|
||
Neonates, including critical care |
|
||
Adult critical care |
|
||
Outpatient and non-acute inpatient settings2 |
|
1 If any individual units of whole blood-derived platelets were transfused, convert these to a pooled equivalent. For example, if 200 platelet pools and 100 individual whole blood-derived platelet units were transfused and 5 individual platelet units are included per pool, then 220 units (200 + [100/5]) should be recorded.
2E.g., outpatient dialysis, rehabilitation, hospice, long term care, etc.
C11. During 2021, did your institution routinely order plasma transfusions to non-pediatric patients based on:
Weight based dosing (e.g., 20mL/kg)
A standard number of units regardless of patient weight (e.g., 4 or 6 units)
Dosage varies based on level of coagulation factor deficiency, INR, or degree of bleeding
Number of units ordered is not consistent with any of the above
C12a. During 2021, did your institution routinely order prophylactic platelet transfusions to non-pediatric patients based on:
A standard number of units regardless of patient weight (e.g., 4 or 6 units)
Dosage varies based on level of thrombocytopenia or degree of bleeding
Number
of units ordered is not consistent with either of the above
C12b. During 2021, did your institution routinely order therapeutic platelet transfusions to non-pediatric patients based on:
A standard number of units regardless of patient weight (e.g., 4 or 6 units)
Dosage varies based on level of thrombocytopenia or degree of bleeding
Number of units ordered is not consistent with either of the above
C13. During 2021, what was the average whole dollar amount your institution paid per unit for the following components? (Include discounts in your calculations. If you do not use a particular component, select “Not applicable”. CPT/HCPCS codes are in parenthesis.)
$ |
Dollar amount paid per unit |
Not applicable
$ |
Dollar amount paid per unit |
Not applicable
$ |
Dollar amount paid per unit |
Not applicable
$ |
Dollar amount paid per unit |
Not applicable
$ |
Dollar amount paid per unit |
Not applicable
$ |
Dollar amount paid per unit |
Not applicable
C14. During 2021, did your institution have a policy to transfuse only leukoreduced components?
Yes
No
C15. During 2021, did your institution have a policy to only transfuse irradiated components?
Yes
No
C16. During 2021, did your institution have an established program to manage patients who refuse any or all blood components for religious, cultural, or personal reasons?
Yes
No
C17a. During 2021, did your institution have a transfusion safety officer (TSO)?
Yes
No
(if
no, skip to C18)
C17b. If yes, how many full-time equivalent TSOs? (Consider two part-time employees as a single full-time equivalent)
|
Number of TSOs |
C17c. Is the TSO employed by your institution or by the blood center?
Institution employee
Blood center employee
C18. During 2021 at your institution, how many whole blood/red blood cell crossmatch procedures were…
Performed by any method |
|
||
Electronic crossmatch |
|
||
Manual serologic crossmatch |
|
||
Automatic serologic crossmatch |
|
C19a. Has your institution implemented typing of red blood cell antigens using a molecular assay (e.g., genotyping)?
Yes
No (if No, skip to C20)
C19b. How many red blood cell units from donors who were genotyped (e.g., using a molecular assay) were transfused by your institution in 2021?
|
Number of units |
C20. How many samples (patient specimens submitted for testing) did your institution receive at the blood bank during 2021?
|
Number of samples |
C21. Does your institution have an electronic system for tracking transfusion-related adverse events?
Yes
No
C22a. Did your institution collect data on sample collection errors (e.g., wrong blood in tube) during 2021?
Yes
No (if no, skip to C23)
C22b. How many transfusion sample collection errors were reported during 2021?
|
Number of errors |
C23. How many transfusion-related adverse reactions were reported to the transfusion service in 2021? (Count only the number of reactions that required any diagnostic or therapeutic intervention.)
Total reactions |
|
Complete below to indicate how many of each type of reaction occurred:
Life-threatening (required major medical intervention1 following transfusion) |
|
||
Transfusion-related acute lung injury (TRALI) |
|
||
Transfusion-associated circulatory overload (TACO) |
|
||
Acute hemolytic transfusion reaction (ABO) |
|
||
Acute hemolytic transfusion reaction (other antibodies) |
|
||
Delayed hemolytic transfusion reaction |
|
||
Delayed serologic transfusion reaction |
|
||
Febrile, non-hemolytic transfusion reaction |
|
||
Hypotensive transfusion reaction |
|
||
Post-transfusion purpura |
|
||
Transfusion-associated dyspnea |
|
||
Transfusion-associated graft-vs-host disease |
|
||
Transfusion transmitted bacterial infection |
|
||
Transfusion transmitted parasitic infection |
|
||
Transfusion transmitted viral infection |
|
||
Mild to moderate allergic reaction |
|
||
Severe allergic reaction |
|
1 Examples include vasopressors, blood pressure support, intubation, or transfer to the ICU
C24. During 2021, which of the following bacterial risk control strategies were used for platelets by the blood collection facility for platelets transfused at your facility?
Primary culture performed no sooner than 24 hours
Large volume, delayed sampling no sooner than 36 hours without secondary
Large volume, delayed sampling no sooner than 48 hours
Pathogen reduction technology
Unknown
C25a. Does your institution perform any kind of pre-transfusion bacterial testing on platelets? This does not include testing performed by the blood collection facility.
Yes
No (if no, skip to C26)
C25b. Indicate what methods are used by your institution to test for bacterial contamination.
|
Secondary culture performed no sooner than Day 3 |
Secondary culture performed no sooner than Day 4 |
Rapid test1 |
Not tested |
Not applicable |
Apheresis platelets |
□ |
□ |
□ |
□ |
□ |
WBD platelets, single |
□ |
□ |
□ |
□ |
□ |
WBD platelets, pooled |
□ |
□ |
□ |
□ |
□ |
1Footnote: FDA cleared rapid tests include PGD Verax and Immunetics BacTx.
C25c. How many confirmed positives and false positives were detected by the following methods during 2021?
Secondary culture performed no sooner than Day 3
Number tested |
|
||
Number of confirmed positives |
|
||
Number of false positives |
|
||
Number of indeterminate results |
|
||
Not applicable |
□ |
Secondary culture performed no sooner than Day 4
Number tested |
|
||
Number of confirmed positives |
|
||
Number of false positives |
|
||
Number of indeterminate results |
|
||
Not applicable |
□ |
Rapid test
Number tested |
|
||
Number of confirmed positives |
|
||
Number of false positives |
|
||
Number of indeterminate results |
|
||
Not applicable |
□ |
C26a. During 2021, did your institution transfuse platelets treated with pathogen reduction technology (PRT)?
Yes
No (if no, skip to end of section C)
C26b. During 2021, how many PRT-treated apheresis platelet units were transfused?
|
|
||
|
|
Note: The following questions were added specifically to gain information on the impact of COVID-19 on blood utilization in 2020.
Supplemental Section C: Impact of COVID-19 Pandemic on Blood Transfusion in 2020
SC1. During each month in 2020, how many units of allogeneic red blood cells did your institution transfuse?
January |
|
||
February |
|
||
March |
|
||
April |
|
||
May |
|
||
June |
|
||
July |
|
||
August |
|
||
September |
|
||
October |
|
||
November |
|
||
December |
|
SC2. During each month in 2020, how many units of apheresis platelets did your institution transfuse?
January |
|
||
February |
|
||
March |
|
||
April |
|
||
May |
|
||
June |
|
||
July |
|
||
August |
|
||
September |
|
||
October |
|
||
November |
|
||
December |
|
1Exclude whole blood derived platelets from the number of units transfused.
Survey Glossary
Apheresis collection procedure: One apheresis collection procedure is one apheresis donation from which multiple units of a single blood products or multiple products can be produced.
Autologous: Self-directed donations.
Deferrals: The number of donors deferred for specific reasons:
Donors deferred for low hemoglobin do not meet the current FDA blood hemoglobin level requirements for blood donation.
Deferrals for other medical reasons may include the use of medications on the medication deferral list, growth hormone from human pituitary glands, insulin from cows (bovine, or beef, insulin), Hepatitis B Immune Globulin (HBIG), unlicensed vaccines, or presenting with physical conditions or symptoms that do not qualify a person to be a blood donor.
High-risk behavior deferrals include deferrals intended to reduce the risk of transmission of infectious diseases including HIV and hepatitis viruses. Examples of questions intended to identify these risks are sexual contact (e.g., men who have sex with men (MSM)) and non-medical injection drug use questions.
Travel deferrals are deferrals for travel to a specific region of the world.
Directed: Directed units are those which have been donated by a family member or friend of the patient as a result of a patient request to be transfused with blood from a specific donor.
Distributed: Units that have fulfilled all processing requirements and have been made available for transfer to customers.
Donation: The collection of a unit of blood or blood component from a volunteer donor.
Dose/Dosage: A quantity administered at one time, such as a specified volume of platelet concentrates.
First-time allogeneic donor: A donor who is donating for the first time at your center.
High-risk behaviors: Behaviors associated with an increased risk of bloodborne viral infection (e.g. nonmedical intravenous drug use, incarceration, high-risk sexual contact
Imported: Units not collected by your institution, but obtained by your institution from another institution for distribution to a transfusion facility.
Modify: Procedures applied by a blood center, hospital blood bank, or transfusion service that may affect the quality or quantity of the final product (e.g., irradiation, leuko-filtration, or production of aliquots of lesser volume).
MSM: Men who have sex with men.
Outdated: Units that expire on your shelf.
Plasma:
Plasma, frozen within 24 hours of phlebotomy (PF24): plasma separated from the blood of an individual donor and placed at -18 C or colder within 24 hours of collection from the donor.
Fresh frozen plasma (FFP): Plasma frozen at -18 degrees C within 8 hours of collection.
Plasma, Jumbo: FFP having a volume greater than 400 mL.
Plasma frozen within 24 hours of phlebotomy and held at room temperature up to 24 hours after phlebotomy (PF24RT24): Plasma held at room temperature for up to 24 hours after collection and then frozen at -18 C or colder.
Thawed plasma: FFP, PF24, or PF24RT24 that has been thawed and held at 1 to 6 C from 1 to up to 5 days after thawing.
Recipient: A unique individual patient receiving a transfusion one or more times in a calendar year.
Repeat allogeneic donor: A donor who has previously donated a blood component.
Severe Donor-Related Adverse Events: Adverse events occurring in donors attributed to the donation process that include, for example, major allergic reaction, arterial puncture, loss of consciousness of a minute or more, loss of consciousness with injury, nerve irritation, etc.1
Transfusion Related Adverse Reactions: An undesirable response or effect in a patient temporally associated with the administration of blood or blood components. For a list of adverse reaction types and case definitions, visit http://www.cdc.gov/nhsn/PDFs/Biovigilance/BV-HV-protocol-current.pdf.
Transfusion Service: A facility that performs, or is responsible for the performance of, the storage, selection, and issuance of blood and blood components to intended recipients.
Whole blood collection procedure: One whole blood collection procedure is one donation of whole blood from which red blood cells, plasma, platelets, and cryoprecipitate can be prepared.
1AABB Donor Hemovigilance Working Group grade 2 or higher (e.g., adverse event with duration > 2 weeks; resulted in limitation in activities of daily living; or required transport to emergency department, sutures, or antibiotics). See https://www.aabb.org/docs/default-source/default-document-library/resources/severity-grading-tool-for-donor-adverse-events.pdf?sfvrsn=ff563263_4.
File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
Author | Bota, Dorothy Afua (CDC/DDID/NCEZID/DHQP) (CTR) |
File Modified | 0000-00-00 |
File Created | 2024-11-27 |